Metabolic · GLP-1 / GIP / glucagon triple agonist (investigational)
Retatrutide
- Drug class
- GLP-1 / GIP / glucagon triple agonist (investigational)
- Status
- Compounded (503A)
- Also known as
- LY3437943, reta
- Reviewed
- 2026-06-01 · Kindr Health Clinical Team
What Retatrutide is studied for
- Investigational chronic weight management
- Type 2 diabetes (phase 2/3)
- Hepatic steatosis (MASLD) reduction
- Cardiometabolic phenotype research
Mechanism of action
Triple agonist of GLP-1, GIP, and glucagon receptors. The glucagon arm increases energy expenditure and may explain the larger weight-loss signal vs. tirzepatide and semaglutide.
Frequently asked questions
Is retatrutide FDA-approved?
No. As of mid-2026 retatrutide is in phase 3 trials (TRIUMPH program) for obesity and type 2 diabetes. Expected FDA decision is 2026–2027.
How much weight do people lose on retatrutide?
In the phase 2 obesity trial, average weight loss at 48 weeks was 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg) — without a clear plateau, suggesting more loss with longer dosing.
How is it different from tirzepatide?
Retatrutide adds glucagon-receptor activation, which raises energy expenditure (basal metabolic rate). Tirzepatide is GLP-1 + GIP only. Side-effect profile is similar but heart-rate elevation is more notable with retatrutide.
What are the side effects?
GI effects (nausea, diarrhea, vomiting) similar to other incretins, plus a small dose-dependent heart-rate increase (~3–6 bpm). Long-term cardiovascular safety is still being studied.
Build the Retatrutide protocol stack
Research protocols commonly pair Retatrutide with the peptides below. Add all three vials to unlock the bundle discount at checkout.
Related peptides in Metabolic
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- GLP-1s in menopauseJournal
- Menopause & weight gainJournal
- SemaglutidePeptide
- TirzepatidePeptide
- GLP-1 weight care serviceMedication
